What is liquid biopsy and how is it used for HER2-Positive Breast Cancer

Understanding Liquid Biopsies for HER2-Positive Breast Cancer

What Is a Liquid Biopsy?

A liquid biopsy is a blood test that detects cancer cells or cancer DNA circulating in your bloodstream. Rather than taking tissue from a tumor (traditional biopsy), doctors analyze what's floating in your blood—making it a less invasive way to understand your cancer.

According to the CancerPatientLab webinars on liquid biopsies, a liquid biopsy works by examining:

• Circulating tumor cells (CTCs) — actual cancer cells in your blood
• Cell-free DNA (cfDNA) — cancer DNA fragments released into circulation
• Exosomes — tiny bubble-like structures that cancer cells release, carrying proteins, DNA, and RNA

How Liquid Biopsies Work for Cancer Monitoring

The Clinical Reasoning: Doctors use liquid biopsies because they offer several advantages over traditional tissue biopsies:

1. Less invasive — just a blood draw, no surgery needed
2. Real-time monitoring — can track how your cancer responds to treatment
3. Early detection of resistance — can identify when cancer cells develop mutations that make them resistant to your current therapy
4. Frequent testing — easier to repeat than tissue biopsies, especially if you're medically fragile

Three Main Uses of Liquid Biopsies

According to the BLOODPAC (Blood Profiling Atlas in Cancer) experts, liquid biopsies serve three primary purposes:

1. Diagnostic Profiling

Similar to a tissue biopsy, a liquid biopsy can identify genetic mutations and biomarkers in your cancer that guide treatment selection. This is particularly valuable for HER2-positive breast cancer patients who may be too medically fragile to undergo surgical biopsy.

2. Treatment Monitoring

As you progress through therapy, liquid biopsies can track whether:

• Your current treatment is working effectively
• Resistance mutations are developing
• It's time to change your therapeutic approach

This monitoring happens through tracking circulating tumor DNA (ctDNA) in your blood—a non-invasive way to ensure therapy is working.

3. Minimal Residual Disease (MRD) Detection

This emerging use can detect early signs of cancer recurrence or resistance before they become clinically apparent on imaging or other tests. This allows doctors to potentially intervene earlier.

Specific Applications for HER2-Positive Breast Cancer

General Approach: For HER2-positive breast cancer specifically, liquid biopsies can:

• Detect HER2 status changes — monitor whether HER2 expression levels are changing during treatment
• Identify emerging resistance — detect when cancer cells develop new mutations that might make them resistant to HER2-targeted therapies (like trastuzumab/Herceptin or pertuzumab/Perjeta)
• Track treatment response — provide real-time feedback on whether your targeted therapy is effectively controlling the cancer
• Comprehensive genomic profiling — identify additional mutations beyond HER2 that might guide precision medicine treatment decisions

Important Considerations: Strengths and Limitations

Advantages:

• More convenient than tissue biopsy
• Can be repeated frequently without surgical risk
• Detects genetic variations across multiple tumor sites (a single tissue biopsy might miss some)
• Helps guide precision medicine treatment decisions

Challenges to Understand:

• False positives and false negatives — like any test, liquid biopsies can sometimes give incorrect results, which may cause unnecessary worry or false reassurance
• Still evolving — while FDA-approved tests exist (like Guardant360 CDx and FoundationOne Liquid CDx), the field is rapidly developing, and not all applications are yet standard of care
• Not a replacement — liquid biopsies complement traditional imaging and tissue testing; they don't replace them

Questions to Ask Your Oncologist

Since liquid biopsies are an emerging tool in breast cancer care, consider asking your HER2-positive breast cancer team:

1. "Would a liquid biopsy be helpful in monitoring my specific HER2-positive breast cancer?"
2. "Are there specific resistance mutations you'd want to track in my case?"
3. "Which liquid biopsy test would you recommend, and why?" (Ask about FDA-approved options and what they measure)
4. "How would the results change my treatment decisions?"
5. "Is this test covered by my insurance, and what's the cost?"
6. "How often would you recommend testing, and what would we be monitoring for?"

Current Evidence and Standards

According to CancerPatientLab webinar experts, liquid biopsies are increasingly being integrated into cancer care, though adoption varies by cancer type. The field is working toward standardized clinical endpoints and clearer guidelines for when and how to use these tests most effectively.

For HER2-positive breast cancer specifically, your oncologist will determine whether a liquid biopsy fits into your personalized treatment plan based on your stage, treatment goals, and individual clinical situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.